G3139: Phase I/II data; Phase III

Updated 1 year follow-up data from GNTA’s Phase I/II trial of G3139 plus Bayer AG’s DTIC-Dome dacarbazine chemotherapeutic showed anti-tumor responses in 6 of 14 evaluable patients, including 1 comple...